Compare Nvidia Corp (NVDA) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nvidia Corp vs TG Therapeutics Inc — how do they compare? Nvidia Corp trades at $229.87 (market cap $5.57T), while TG Therapeutics Inc trades at $54.98 (market cap $8.16B). The key difference: Nvidia Corp is far larger — about 682.6× TG Therapeutics Inc's market cap, and Nvidia Corp pays a 0.43% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Nvidia Corp for 115 Days and TG Therapeutics Inc for 16 Days on average.
| NVDA | TGTX | |
|---|---|---|
Market Cap | $5.57T | $8.16B |
Volume | 117,720,595 | 1,735,121 |
Sector | Technology | Health |
52-Week High | $239.27 | $59.06 |
52-Week Low | $165.17 | $26.94 |
Typical Hold Time | 115 Days | 16 Days |
Enterprise Value | $5.54T | $8.37B |
Dividend Yield | 0.43% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NVIDIA (NVDA) trades at $229.25, down 3.42% over the past day amid a broader tech sell-off. The stock maintains a bullish technical signal with strong support near $228 and resistance at $235. Fundamentally, the company reported record revenue of $130.50B in 2025, with net income surging to $72.88B, reflecting a 55.84% profit margin. Recent quarterly earnings have consistently beaten expectations, with Q2 2026 EPS of $2.22 surpassing the $2.09 estimate. Analyst sentiment remains overwhelmingly positive, with a consensus price target of $339.17 implying significant upside.
NVDA's outlook is supported by robust AI chip demand and accelerating revenue growth, projected to reach $303.0B in 2026. However, risks include heightened competition, potential peak AI spending, and geopolitical tensions affecting market sentiment. The stock presents a compelling growth opportunity but requires monitoring of execution risks and macroeconomic headwinds.
TG Therapeutics (TGTX) trades at $54.80, up 3.49% today, but faces a bearish technical signal with recent earnings misses. Revenue growth is strong, with 2026 guidance raised to $950M for BRIUMVI, and net income margins exceed 55%. However, cash flow was negative in 2025, and a shareholder litigation investigation adds near-term uncertainty.
The outlook is mixed: analyst consensus is bullish with an $80.50 price target, but execution risks and earnings volatility persist. Upside hinges on BRIUMVI market share gains and subcutaneous formulation progress, while legal and competitive pressures pose threats to shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nvidia Corp
NVIDIA Corporation designs, develops, and markets three dimensional (3D) graphics processors and related software. The Company offers products that provides interactive 3D graphics to the mainstream personal computer market.
Read more on NVDA →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
